Dr Andrew Spragg, chief executive officer and founder of Aquapharm Biodiscovery, has won a top Scottish award for innovation in recognition of the potential for an antibiotic compound developed by his company to combat infections such as MRSA. Dr Spragg has received the Gannochy Trust Innovation Award, which carries a £50,000 cash prize and a gold medal, from the Royal Society of Edinburgh
Newcastle-based e-Therapeutics plans to join London’s Alternative Investment Market in the near future. The drug discovery company owns candidate drugs in five therapeutic areas, which together represent a potential market of more than $80bn.
Two portfolio companies of technology transfer business Biofusion have been sold to a privatelyowned pharmaceutical company just days after Biofusion raised its equity holdings in both companies to 50%. The sales of Cardiff Biologicals and Cardiff ProTides to Morvus Technology means that Biofusion now has a remaining portfolio of 23 companies from its partnerships with Sheffield and Cardiff universities.
A Department of Trade and Industry-funded programme to develop materials to help complex surgical and regenerative medicine applications has proved a success, according to NovaThera – a Cambridge-based company involved in the programme.
Imperial College spinout deltaDOT has received a further £3m from investors, completing its fourth round of funding. The funds will be used to increase production capacity for the company’s ‘Peregrine’ system – a high performance capillary electrophoresis instrument for the separation of proteins, peptides, nucleic acids, small molecules and pathogens